List of Excipients in Branded Drug BIAXIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	BIAXIN	clarithromycin	54868-3820	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	BIAXIN	clarithromycin	54868-3820	D&C YELLOW NO. 10
Physicians Total Care Inc	BIAXIN	clarithromycin	54868-3820	FD&C BLUE NO. 1
Physicians Total Care Inc	BIAXIN	clarithromycin	54868-3820	HYDROXYPROPYL CELLULOSE

BIAXIN Clarithromycin Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

BIAXIN, the original branded clarithromycin product, has limited direct brand protection because clarithromycin composition-of-matter and core product patents expired years ago. The commercial opportunity is in differentiated excipient systems: palatable pediatric suspensions, stable ready-to-use liquids, once-daily modified-release tablets, low-sugar formulations, and global products adapted to regional excipient restrictions. The strongest near-term opportunities are generic substitution, contract manufacturing, hospital supply, and reformulation rather than recovery of the legacy BIAXIN brand.

What is BIAXIN and which clarithromycin formulations are commercially relevant?

BIAXIN is the brand name for clarithromycin, a macrolide antibiotic used for respiratory tract infections, skin and soft-tissue infections, and eradication of Helicobacter pylori in combination regimens. FDA-approved dosage forms have included immediate-release tablets, extended-release tablets marketed as BIAXIN XL, and oral granules for suspension. [1][2]

Product format	Typical strength	Administration profile	Excipient-driven commercial issue
Immediate-release tablet	250 mg, 500 mg	Twice daily	Tablet size, swallowing, color, coating, manufacturability
Extended-release tablet	500 mg	Once daily with food	Release control, food effect, matrix robustness
Oral suspension	125 mg/5 mL, 250 mg/5 mL	Pediatric and adult use	Taste, sedimentation, reconstitution stability, preservative strategy
Combination H. pylori pack	Varies	Multiple daily products	Pack integration, adherence, taste, tablet compatibility

The reference product’s dosage-form architecture is commercially important even where the underlying active ingredient is no longer protected. Generic applicants must match critical quality attributes, dissolution behavior, bioequivalence, stability, and, where applicable, qualitative and quantitative excipient requirements under the applicable FDA pathway. [3]

What excipients are used in BIAXIN formulations?

The specific excipients depend on the dosage form and strength. FDA labeling identifies excipients used in BIAXIN tablets, BIAXIN XL tablets, and BIAXIN granules for oral suspension. Commercial formulations generally use a combination of fillers, binders, disintegrants, lubricants, coating agents, suspending agents, sweeteners, and flavoring systems. [1][2]

Immediate-release tablets

The immediate-release tablet platform has historically used conventional solid-dose excipients such as:

• Microcrystalline cellulose and pregelatinized starch as fillers and compression aids
• Croscarmellose sodium as a disintegrant
• Povidone as a binder
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Hypromellose, titanium dioxide, talc, and colorants in the film coating

This excipient system is not technically difficult to reproduce. The main development risks are powder flow, content uniformity, tablet hardness, disintegration, and dissolution consistency. Clarithromycin has a strong bitter taste and can create a coating or handling challenge if the drug is exposed at the tablet surface.

Extended-release tablets

BIAXIN XL uses a modified-release tablet design intended for once-daily dosing. The formulation relies on hydrophilic and matrix-forming excipient behavior rather than a simple immediate-release tablet. Label disclosures identify excipients including hypromellose, sodium alginate, lactose monohydrate, povidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, talc, titanium dioxide, and colorants. [2]

The strategic formulation issue is the interaction among:

• Polymer hydration
• Tablet porosity
• Compression force
• Drug loading
• Gastrointestinal pH
• Food intake
• Transit time
• Tablet size and mechanical strength

A modified-release clarithromycin product can fail through dose dumping, excessive food sensitivity, incomplete drug release, or dissolution drift after scale-up. Polymer grade selection and granulation process control are more important than simply matching the listed excipient names.

Oral suspension

The oral suspension platform uses a broader excipient package. The BIAXIN granules label identifies excipient classes including sucrose, carbomer, hypromellose, xanthan gum, colloidal silicon dioxide, povidone, polyoxyl 40 stearate, sorbitan monooleate, citric acid, castor oil, maltodextrin, titanium dioxide, and flavor-related components. [1]

The commercial purpose of this system is to manage:

• Poor water solubility
• Sedimentation
• Redispersibility
• Bitter taste
• Reconstitution behavior
• Microbial control
• Short in-use shelf life
• Dose uniformity after repeated shaking

The suspension is the most attractive area for excipient-led differentiation because caregivers and pharmacists experience the product’s taste, pourability, sedimentation, and storage burden directly.

What excipient strategies can improve clarithromycin products?

The most valuable strategies are those that solve a clinical-use problem without creating a new regulatory or manufacturing burden.

Taste masking for pediatric clarithromycin

Clarithromycin is intensely bitter. A successful pediatric product must prevent immediate drug release in the oral cavity while allowing rapid release after swallowing.

Potential technologies include:

1. Polymer-coated drug particles. Ethylcellulose, methacrylate copolymers, or other aqueous dispersions can reduce surface bitterness.
2. Ion-exchange resin complexes. Clarithromycin can be associated with a resin and released under gastrointestinal conditions.
3. Lipid or wax barriers. These can improve palatability but may complicate dissolution and suspension uniformity.
4. Cyclodextrin or molecular-complex approaches. These may reduce free drug activity in the mouth but require careful evaluation of dose loading and stability.
5. Flavor and sweetener systems. High-intensity sweeteners, fruit flavors, and acidulants can reduce perceived bitterness but rarely solve the problem alone.

The strongest product concept is usually a dual-control system: particle-level taste masking combined with a suspending vehicle and a targeted flavor platform. A flavor-only reformulation is unlikely to provide a durable competitive advantage.

Low-sugar and sugar-free suspensions

Sucrose improves palatability, viscosity, and mouthfeel but creates commercial limitations for patients with diabetes, dental concerns, or restricted sugar intake. A low-sugar formulation could use combinations of:

• Sorbitol or maltitol
• Sucralose or acesulfame potassium
• Xanthan gum
• Microcrystalline cellulose and carboxymethylcellulose systems
• Polyols with controlled water activity

The principal risks are osmolarity, gastrointestinal tolerability, hygroscopicity, microbial growth, and changes in sedimentation. A sugar-free product must also maintain acceptable taste after clarithromycin’s bitterness becomes more prominent in the absence of sucrose.

Ready-to-use liquid formulations

A ready-to-use suspension would eliminate pharmacy reconstitution and reduce caregiver error. The principal formulation barrier is chemical and microbiological stability in an aqueous environment. Clarithromycin degradation can be affected by pH, temperature, light, oxidation, and interactions with surfactants or polymers.

A commercially viable ready-to-use product would need:

• A validated antimicrobial-preservation system
• Container-closure compatibility
• Controlled headspace and oxygen exposure
• Demonstrated dose uniformity throughout the bottle
• An in-use stability period suitable for the intended treatment duration
• A dispensing device calibrated to the labeled dose

Because the label-approved granules are reconstituted before use, a ready-to-use product could create a meaningful convenience advantage if stability and taste are solved without materially increasing cost.

Modified-release and gastroretentive systems

Once-daily clarithromycin reduces pill burden compared with twice-daily immediate-release dosing. A next-generation extended-release product could use:

• Hydrophilic matrix polymers
• Multiparticulate coated beads
• Osmotic delivery
• Gastroretentive floating systems
• Size- or density-modified pellets
• Amorphous or solid-dispersion technology

The commercial case is weaker than it was for the original BIAXIN XL launch because generic immediate-release clarithromycin is inexpensive and antibiotic prescribing has shifted toward stewardship and narrower indications. A modified-release product therefore needs a defined advantage in adherence, tolerability, or combination-pack convenience.

What FDA regulatory pathway applies to a generic BIAXIN product?

A conventional generic clarithromycin product would generally be submitted under an abbreviated new drug application, provided the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference-listed drug. FDA’s Orange Book identifies reference products, dosage forms, strengths, and patent or exclusivity information. [3]

Regulatory priorities by dosage form

Product	Main regulatory burden	Key analytical package
Immediate-release tablet	Conventional ANDA equivalence	Assay, impurities, dissolution, bioequivalence
Extended-release tablet	Release-profile and food-effect control	Multiple dissolution conditions, fed/fasted studies, alcohol dose-dumping assessment where applicable
Oral suspension	Product performance and in-use stability	Particle size, redispersibility, viscosity, dose uniformity, microbial limits, taste strategy
Novel taste-masked product	Potentially greater formulation complexity	Comparative dissolution, particle characterization, stability, bioequivalence
New ready-to-use liquid	May require a new-drug or hybrid strategy depending on reference and claims	Full stability, preservative effectiveness, container closure, clinical or comparative studies as required

An excipient change can be commercially attractive but may move the product outside a straightforward generic strategy. FDA’s Inactive Ingredient Database can support precedent analysis, but prior use of an excipient does not eliminate the need to establish suitability at the proposed route, dose, concentration, and patient population. [4]

When does BIAXIN lose exclusivity, and what is the patent position?

The core clarithromycin patent estate is expired. The relevant commercial barriers are now formulation execution, regulatory approval, manufacturing scale, and market access rather than basic active-ingredient patent protection.

Protection category	Current strategic relevance
Clarithromycin composition of matter	Expired
Conventional immediate-release formulation patents	Generally expired or commercially weak
Legacy extended-release patents	Likely expired or near the end of practical value, depending on jurisdiction and claim scope
Method-of-use patents	Limited value where the underlying indications are old and generic substitution is established
Pediatric exclusivity	Not a durable current barrier for the legacy brand
Trademark rights in BIAXIN	Brand-specific, but insufficient to prevent generic clarithromycin entry

Orange Book listings and FDA product records should be reviewed for any remaining listed patents, discontinued product status, and reference-product designation before a filing or launch decision. The business case should not assume that a legacy BIAXIN patent number creates an enforceable barrier without claim-by-claim review and confirmation of expiration, terminal disclaimers, maintenance fees, and litigation history. [3]

What generic entry risks exist for BIAXIN and clarithromycin?

Generic entry risk is high for immediate-release clarithromycin tablets and established oral suspension strengths. The market has low active-ingredient barriers and mature manufacturing processes.

Paragraph IV challenges

A Paragraph IV certification could be relevant only if an unexpired Orange Book-listed patent remains associated with the selected reference product. For the legacy immediate-release product, the main risk is not a current compound patent but possible formulation or use claims tied to a particular dosage form.

For extended-release clarithromycin, the key questions are:

• Whether the reference product remains active in the Orange Book
• Whether the listed patent claims the release mechanism or only a narrow formulation
• Whether the proposed generic uses a non-infringing polymer or manufacturing process
• Whether the product must demonstrate bioequivalence to an extended-release reference
• Whether a controlled-release patent has expired or been disclaimed

A generic applicant may use a Paragraph IV certification, Section viii carve-out, or Paragraph III certification depending on the listed patent and proposed labeling. The commercial value of a litigation strategy is limited when the reference product has low sales or when multiple generic suppliers already compete.

Litigation and settlement exposure

No widely recognized current litigation barrier should be assumed for legacy BIAXIN products. Any transaction or launch plan should rely on current court dockets, FDA Orange Book data, and product-specific patent certifications rather than historical BIAXIN litigation references.

A settlement agreement involving a discontinued brand may have little practical value unless it controls an active authorized-generic supply arrangement, a formulation license, or access to a manufacturing platform.

Which companies are challenging or competing with BIAXIN?

The practical competitors are generic clarithromycin manufacturers and alternative macrolide products rather than branded BIAXIN licensees.

Competitive group	Competitive basis
Generic clarithromycin tablet suppliers	Lowest acquisition cost and broad wholesaler access
Generic oral suspension suppliers	Pediatric availability, flavor, stability, and pharmacy convenience
Extended-release clarithromycin suppliers	Once-daily dosing and reference-product substitution
Azithromycin manufacturers	Lower dosing frequency and broad outpatient use
Amoxicillin-based regimens	Cost, familiarity, and use in H. pylori treatment
Doxycycline suppliers	Alternative respiratory and skin-infection positioning
Hospital procurement vendors	Supply reliability, contract pricing, and shortage management

For an excipient supplier, the most relevant customers are generic manufacturers with existing clarithromycin approvals, contract development and manufacturing organizations, and regional pharmaceutical companies seeking pediatric or modified-release products.

What commercial opportunities exist in BIAXIN excipients?

Opportunity 1: Taste-masked pediatric granules

This is the clearest formulation opportunity. A differentiated system could offer lower bitterness, improved redispersibility, reduced sugar, and longer post-reconstitution stability. The commercial model could include an excipient package, a development service, or a formulation license.

The value proposition should be measured through:

• Electronic or trained-panel bitterness scores
• First-dose acceptance
• Dose recovery from oral syringes
• Sedimentation rate
• Redispersibility after storage
• Stability under temperature excursions
• Comparative pharmacy preparation time

Opportunity 2: Sugar-free or reduced-sugar suspension

This product could target pediatric patients, diabetes-conscious caregivers, and international markets with reduced-sugar preferences. The strongest differentiation would combine acceptable taste with stable viscosity and a familiar dosing presentation.

Opportunity 3: Single-dose or unit-dose hospital presentations

Unit-dose oral syringes, sachets, or reconstitutable powder packs could reduce dosing error and pharmacy labor. Hospital buyers may value standardized dosing and reduced preparation time more than a new tablet technology.

Opportunity 4: Extended-release polymer platforms

A polymer supplier could offer a validated matrix system for once-daily clarithromycin or other poorly soluble antibiotics. The commercial opportunity is broader than BIAXIN because the same polymer platform could support several oral modified-release products.

Opportunity 5: Global excipient substitution

A formulation that depends on a single regionally restricted colorant, animal-derived material, or difficult-to-source polymer has supply-chain risk. A dual-source excipient architecture can support launches across the United States, Europe, Asia, and emerging markets.

Excipient selection should account for:

• Ph. Eur., USP-NF, and JP monograph compliance
• Nitrosamine and elemental impurity controls
• Allergen and animal-origin declarations
• TSE/BSE documentation
• Residual solvent limits
• Regional colorant restrictions
• Pediatric acceptability
• Supply continuity and manufacturing-site redundancy

How strong is the patent estate for an excipient-based BIAXIN reformulation?

A simple excipient substitution is unlikely to create strong, durable patent protection. Patent strength improves when the invention claims a defined technical result tied to a reproducible formulation architecture.

Potentially stronger claim categories include:

• A taste-masked clarithromycin particle with defined dissolution in simulated saliva and gastric media
• A suspension with specified sedimentation, viscosity, particle-size distribution, and redispersibility
• A sugar-free product with a defined preservative and polymer system
• A modified-release tablet with a specified dissolution profile across pH conditions
• A stable ready-to-use liquid with a defined pH range and degradation limit
• A manufacturing process that produces a controlled particle-size distribution or coating thickness
• A container-closure system that preserves potency and microbial quality during in-use storage

Patent claims should avoid covering only a list of conventional excipients. A stronger estate links composition, process, performance, and measurable product attributes. Regulatory exclusivity may also be limited if the reformulation is submitted as a generic rather than a full new drug.

How does BIAXIN compare with azithromycin for commercial formulation strategy?

Factor	Clarithromycin	Azithromycin
Taste burden	High	Also significant, particularly in pediatric liquids
Immediate-release dosing	Commonly twice daily	Often once daily
Modified-release opportunity	Moderate	Lower practical need because standard dosing is already convenient
Pediatric suspension opportunity	High	High
Generic price pressure	High	High
Excipient differentiation	Taste, suspension, release control	Taste, suspension, dose concentration
Brand recovery potential	Low	Low
Best commercial channel	Generic, hospital, pediatric, international	Generic, pediatric, outpatient

Clarithromycin has a stronger rationale for excipient work in extended-release products because the active ingredient has a recognized twice-daily immediate-release history. Azithromycin has a stronger baseline convenience position, so a clarithromycin reformulation must demonstrate a clear adherence or tolerability benefit.

What is the revenue exposure and launch outlook?

Revenue exposure depends on whether the product targets the low-margin commodity generic market or a differentiated dosage form.

Product strategy	Margin outlook	Development risk	Market outlook
Standard 250/500 mg tablets	Low	Low	Commodity
Standard oral suspension	Low to moderate	Moderate	Stable pediatric demand
Taste-masked suspension	Moderate to high	Moderate to high	Differentiated niche
Sugar-free ready-to-use liquid	Moderate to high	High	Potentially attractive
Extended-release tablet	Moderate	High	Limited by generic competition
Hospital unit-dose presentation	Moderate	Moderate	Procurement-driven
Excipient platform licensing	High potential	Moderate	Scalable across products

The most defensible investment thesis is a platform approach. A company that develops taste masking, suspension stabilization, and low-sugar vehicle technology for clarithromycin can reuse the platform for other bitter antibiotics, including amoxicillin-clavulanate, metronidazole, azithromycin, and selected pediatric antivirals.

Key Takeaways

• BIAXIN is clarithromycin, and its core patent protection is expired.
• Immediate-release tablets are technically mature and exposed to intense generic price competition.
• Oral suspension is the strongest area for excipient-led differentiation.
• The highest-value problems are bitterness, sedimentation, redispersibility, sugar reduction, and in-use stability.
• BIAXIN XL demonstrates the commercial relevance of modified-release excipient systems, but the market case is weaker than for pediatric reformulation.
• Simple excipient substitution is unlikely to create a strong patent estate.
• Performance-based formulation claims tied to dissolution, taste masking, stability, or suspension behavior offer better protection.
• FDA Orange Book and Drugs@FDA records should control product-specific conclusions on current listings, reference status, patents, and exclusivity.
• The best commercial route is a differentiated generic, hospital presentation, or licensable excipient platform rather than a direct branded BIAXIN relaunch.

FAQs

Is clarithromycin oral suspension still commercially attractive?

Yes, but mainly through taste, stability, dosing convenience, and supply reliability. Standard suspension products face generic price pressure.

Can a sugar-free BIAXIN formulation obtain new patent protection?

Potentially. Protection would depend on a novel and non-obvious composition or process with demonstrated performance, not merely replacement of sucrose with a conventional sweetener.

Are BIAXIN XL formulation patents still a major generic barrier?

They should not be presumed to be a current barrier. The relevant patents, expiration dates, terminal disclaimers, and Orange Book listings require product-specific confirmation.

What excipient is best for clarithromycin taste masking?

No single excipient is universally best. Polymer-coated particles, ion-exchange complexes, lipid barriers, and optimized sweetener-flavor systems should be screened against dissolution, stability, and pediatric palatability requirements.

Could a clarithromycin ready-to-use liquid compete with tablets?

Yes, in pediatric and caregiver-focused markets if it provides materially better taste, dosing accuracy, stability, and convenience. It would face higher formulation and regulatory risk than a conventional dry suspension.

References

1. U.S. Food and Drug Administration. (n.d.). BIAXIN (clarithromycin) tablets and granules for oral suspension prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). BIAXIN XL (clarithromycin extended-release tablets) prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2014). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

6. U.S. Food and Drug Administration. (2018). Clinical relevance of dissolution testing in abbreviated new drug applications. https://www.fda.gov/regulatory-information/search-fda-guidance-documents